Be the first person to write a business review for ALK-Abello A/S

Allergan Limited company is the UK subsidiary of US pharmaceutical company Allergan. Like its American parent, the company is focused on eye and skin care medications and neurological disorder treatments. Products available in the UK include eye twitching and wrinkle removing drug Botox, glaucoma treatment Lumigan, steroidal eye medication Pred Forte, allergy drug Relestat, and psoriasis treatment Zorac. The company is also the headquarters of its parent's European research and development operations; its efforts target areas including retinal disease, skin disorders, and pain.

Allon Therapeutics Inc. company's primary focus is on developing treatments for Alzheimer's and other neurodegenerative diseases that lead to memory loss and cognitive impairment. Its lead candidate AL-108 is a nasal spray that has shown some efficacy in clinical trials in treating the symptoms of patients with amnestic mild cognitive impairment, a precursor to Alzheimer's. Allon has collaborations with the National Institute on Aging, the Alzheimer's Disease Cooperative Study, the Institute for the Study of Aging, and the Tel Aviv University.

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical ingredients. Amphastar’s Management Team takes pride in the Company’s “3H” commitment to "High Quality, High Efficiency and High Technology". In keeping with this pledge of excellence to the consumer, Amphastar will continue to invest in state-of-the-art equipment, research & development, facilities, and the advancement of their employees.

Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

Anesiva, Inc. (Anesiva) is a biopharmaceutical company focused on the development and commercialization of therapeutic treatments for pain management. Its portfolio includes two products. Adlea, a long-acting, site-specific, non-opioid analgesic, is being developed for moderate to severe pain, and has completed multiple Phase II trials in post-surgical, musculoskeletal and neuropathic pain and Phase III trials in bunionectomy and total knee arthroplasty (TKA, or total knee replacement surgery). The Company is initially pursuing an indication for Adlea for the management of acute pain associated with orthopedic surgeries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system, was approved by the Food and Drug Administration (FDA) in August 2007, to reduce the pain associated with peripheral intravenous (IV) insertions or blood draws in children 3 to 18 years of age. Zingo was approved in January 2009, to reduce the pain associated with blood draws in adults.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.